The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 20 06 2018
accepted: 16 01 2019
entrez: 1 5 2019
pubmed: 1 5 2019
medline: 24 12 2019
Statut: epublish

Résumé

Extraintestinal manifestations (EIM) involving joints, skin, eyes and liver represent an important problem in the treatment of IBD patients. The aim of this study was to identify factors that are associated with the occurrence of joint EIM and therefore allow an early diagnosis and guide medical treatment. We studied clinical and epidemiological data from 3298 patients included in the Swiss IBD Cohort Study (SIBDCS), 1860 suffered from Crohn's disease (CD) and 1438 from ulcerative colitis or IBD unclassified (UC/IBDU). We found female gender as well as a longer disease duration and activity (specified as CDAI or MTWAI, respectively) to be related to the appearance of arthritis/arthralgia, but also sacroiliitis/ankylosing spondylitis in IBD patients. IBD patients with arthritis/arthralgia or sacroiliitis/ankylosing spondylitis were more often treated with anti-TNF and patients with arthritis/arthralgia underwent more often IBD-related surgeries. We revealed that eye or skin EIM were more frequent in patients with arthritis/arthralgia or sacroiliitis/ankylosing spondylitis. In multivariate analysis, we confirmed female gender, longer disease duration, IBD-related surgery, presence of other EIM and treatment with anti-TNF to be independent risk factors for the onset of arthritis/arthralgia in CD and UC/IBDU patients. In this study, we demonstrated that markers for a more severe disease course were associated with the onset of joint EIM in IBD patients. Our data suggest that in particular females under anti-TNF treatment and patients suffering from non-joint and/or IBD-related surgery should be close and carefully monitored for presence of arthritis or sacroiliitis/ankylosing spondylitis.

Sections du résumé

BACKGROUND/AIMS
Extraintestinal manifestations (EIM) involving joints, skin, eyes and liver represent an important problem in the treatment of IBD patients. The aim of this study was to identify factors that are associated with the occurrence of joint EIM and therefore allow an early diagnosis and guide medical treatment.
METHODS
We studied clinical and epidemiological data from 3298 patients included in the Swiss IBD Cohort Study (SIBDCS), 1860 suffered from Crohn's disease (CD) and 1438 from ulcerative colitis or IBD unclassified (UC/IBDU).
RESULTS
We found female gender as well as a longer disease duration and activity (specified as CDAI or MTWAI, respectively) to be related to the appearance of arthritis/arthralgia, but also sacroiliitis/ankylosing spondylitis in IBD patients. IBD patients with arthritis/arthralgia or sacroiliitis/ankylosing spondylitis were more often treated with anti-TNF and patients with arthritis/arthralgia underwent more often IBD-related surgeries. We revealed that eye or skin EIM were more frequent in patients with arthritis/arthralgia or sacroiliitis/ankylosing spondylitis. In multivariate analysis, we confirmed female gender, longer disease duration, IBD-related surgery, presence of other EIM and treatment with anti-TNF to be independent risk factors for the onset of arthritis/arthralgia in CD and UC/IBDU patients.
CONCLUSION
In this study, we demonstrated that markers for a more severe disease course were associated with the onset of joint EIM in IBD patients. Our data suggest that in particular females under anti-TNF treatment and patients suffering from non-joint and/or IBD-related surgery should be close and carefully monitored for presence of arthritis or sacroiliitis/ankylosing spondylitis.

Identifiants

pubmed: 31039159
doi: 10.1371/journal.pone.0211554
pii: PONE-D-18-18372
pmc: PMC6490952
doi:

Substances chimiques

Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0211554

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nature. 2012 Nov 1;491(7422):119-24
pubmed: 23128233
J Crohns Colitis. 2016 Apr;10(4):455-61
pubmed: 26721937
Inflamm Bowel Dis. 2015 Aug;21(8):1982-92
pubmed: 26154136
Curr Rev Musculoskelet Med. 2011 Sep;4(3):123-31
pubmed: 21710141
Gut. 1998 Mar;42(3):387-91
pubmed: 9577346
Eur Rev Med Pharmacol Sci. 2012 Jul;16(7):890-901
pubmed: 22953637
Gastroenterol Nurs. 2017 Nov/Dec;40(6):496-503
pubmed: 28727666
Indian J Gastroenterol. 2015 Sep;34(5):387-94
pubmed: 26614005
J Crohns Colitis. 2016 Mar;10(3):239-54
pubmed: 26614685
Lancet. 2016 Jan 9;387(10014):156-67
pubmed: 26490195
Ann Ital Chir. 2009 Jul-Aug;80(4):293-8
pubmed: 19967888
J Crohns Colitis. 2010 Sep;4(3):257-68
pubmed: 21122514
Dig Dis Sci. 2011 Jan;56(1):183-7
pubmed: 20458624
Am J Gastroenterol. 1998 Feb;93(2):144-9
pubmed: 9468230
Am J Gastroenterol. 2011 Jan;106(1):110-9
pubmed: 20808297
Scand J Gastroenterol. 2015 Mar;50(3):300-5
pubmed: 25535653
Inflamm Bowel Dis. 2019 Jan 10;25(2):394-402
pubmed: 30085159
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Am J Gastroenterol. 1990 Jun;85(6):711-6
pubmed: 2353691
World J Gastroenterol. 2006 Aug 14;12(30):4819-31
pubmed: 16937463
Int J Epidemiol. 2009 Aug;38(4):922-31
pubmed: 18782896
Bull Hosp Jt Dis (2013). 2016 Sep;74(3):185-92
pubmed: 27620540
Inflamm Bowel Dis. 2015 Aug;21(8):1794-800
pubmed: 26020601
Scand J Gastroenterol. 2018 Oct - Nov;53(10-11):1250-1256
pubmed: 30353756
Eur J Gastroenterol Hepatol. 2018 Jun;30(6):598-607
pubmed: 29360691
Inflamm Bowel Dis. 2015 Nov;21(11):2598-604
pubmed: 26244648
Scand J Gastroenterol. 2001 Dec;36(12):1307-13
pubmed: 11761022
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206
pubmed: 27801751
J Crohns Colitis. 2016 Feb;10(2):166-75
pubmed: 26512134

Auteurs

Aimee Hiller (A)

Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Luc Biedermann (L)

Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Nicolas Fournier (N)

Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland.

Matthias Butter (M)

Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Stephan R Vavricka (SR)

Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Adrian Ciurea (A)

Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.

Gerhard Rogler (G)

Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Michael Scharl (M)

Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH